Type I Interferons (IFN-alpha/beta) are produced primarily in response to viral infection by Natural IFN-producing cells (IPCs) as part of the host immune response. IFNs can also inhibit the development of tumors. IFN-beta binding results in the activation of the tyrosine kinases Jak1 and Tyk2, phosphorylation of members of the STAT family of transcription factors, and the transcription and expression of the immune response genes. More recently, several members of the toll-like receptor (TLR) family were found to stimulate the production IFN-beta. IFN-beta is currently used clinically for treatment of tumors, infections and multiple sclerosis.
- Numéro d’adhésion
- P70499
- Plage de dosage
- 15.63 to 1000 pg/mL
- Sensibilité du dosage
- 9.38 pg/mL
- Conjugué
- HRP
- Type de produit
- ELISA
- Type d’échantillon
- Plasma, Serum
- À utiliser avec (équipement)
- Colorimetric Microplate Reader
- Identification génétique (Entrez)
- 24481
- Symbole de gène(s)
- Ifnb1
- Coefficient de variation inter-dosage
- <10
- Coefficient de variation intra-dosage
- <10
- Contenus des kits
- Micro ELISA Plate (Dismountable), Reference Standard, Concentrated Biotinylated Detection Ab(100x), Concentrated HRP Conjugate (100x), Reference Standard & Sample Diluent, Biotinylated Detection Ab Diluent, HRP Conjugate Diluent, Concentrated Wash Buffer(25x), Substrate Reagent, Stop Solution, Plate Sealer, Product Description, Certificate of Analysis
- Marqueur ou colorant
- Biotin
- Quantité
- 96 Tests
- État réglementaire
- RUO
- Volume d’échantillon
- Plasma: 100 μL, Serum: 100 μL
- Conditions de stockage
- Refer to product documentation for component specific storage temperature.
- Cible
- IFN beta
- Heure du test
- 1 hr. 20 min.
- Durée totale du dosage
- 3 hr. 30 min.
